reduced metastasis of intravenously injected B16 melanoma cells and a substantial survival benefit were reported if steady adjuvant 60 mg/kg/day anti angiogenic HC-030031 was given following the angiogenic sunitinib program. It mainly wants to demonstrate that temporary, MTD anti angiogenic therapy could be also exert and less successful undesireable effects, while it’s not obvious from the title and abstract with this report. These data support the theory that more isn’t always more, in particular, if the anti angiogenic effect of a drug is wanted. The useful anti angiogenic effects of low dose sustained programs over less frequent but high doses established for a broad range of agencies must influence the development of clinical Phase I studies, which remain based on determination of the MTD principle. In cancer research, experimental data usually precede clinical data. In the case of sunitinib, a second generation multiple focused RTKi that potently inhibits VEGF and PDGF signaling, clinical antimetastatic activity is already described, e. g., for renal cell carcinoma in a number of different metastatic sites. A current Phase III clinical trial in metastatic renal cell carcinoma has shown Endosymbiotic theory the superior activity of sunitinib monotherapy compared to interferon alpha resistant therapy, the last therapy of preference with this chemoresistant cancer. Consistent with its powerful anti angiogenic and anti metastatic action, sunitinib treatment was found to diminish rapidly the amount of while the number of circulating endothelial cells was elevated in peripheral blood of renal cell cancer patients circulating hematopoietic progenitor cells. In conclusion, from recent scientific information on 10,000 patients treated with anti VEGF therapy, it’s impossible that VEGF qualified therapy accelerates metastasis…. In addition, experimental evidence is offered for the beneficial aftereffects of radiotherapy and combined sunitinib for the orthotopic murine style of breast cancer metastasis in bone treatment. Sunitinib monotherapy is further reported to effortlessly prevent tumefaction growth and osteolysis in yet another CAL-101 PI3K inhibitor breast cancer bone metastasis model. More over, it had been recently shown that hypoxia caused cancer invasion and metastasis could possibly be efficiently blocked by inhibition of VEGF signaling via management of sunitinib or VEGFR2 morpholinos. Finally, encouraging clinical studies with sunitinib in metastatic breast and prostate cancer are ongoing. Ergo, the beneficial results of sunitinib anti angiogenic treatment in inhibition of metastatic cancer diseases are encouraging, and we assume that the following generations of multitargeted RTKis with enhanced inhibitory and toxicity profiles can significantly influence the management of metastatic diseases.